BioSpace News Archive

ValGenesis, Inc and QualiTech Engineering and Compliance have announced a strategic partnership to deliver best-in-class digital validation solutions and services for life science companies in Greece.

NovoPath LLC, a leader in laboratory information systems, is proud to announce new solutions for oncology diagnostic laboratories.

Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that it will be presenting at the 2nd Annual mRNA-Based Therapeutics Summit Europe Conference in Berlin, Germany, which will be held January 24-26, 2023.

Gameto, a biotechnology company using cell engineering to develop therapeutics for diseases of the female reproductive system, announced the appointment of David McCulloh, Ph.D., H.C.L.D., C.C. as Vice President of Embryology.

Noven Pharmaceuticals. Inc., (Noven) announced today that XELSTRYM™ (dextroamphetamine) transdermal system, CII, the first and only FDA-approved amphetamine patch for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults and pediatric patients six years and older, will be available across the U.S. for healthcare professionals to prescribe later in the first quarter of 2023.

SELUTION SLR™, MedAlliance’s novel sirolimus-eluting balloon, has received conditional FDA Investigational Device Exemption (IDE) approval to initiate its pivotal clinical trial for the treatment of coronary de novo lesions.

Vivalink, a leading provider of digital healthcare solutions, announces its biometric data platform has been successfully integrated into Elevate Addiction Services’ drug and alcohol in-patient detox treatment program.

NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi.

Cerveau Technologies, Inc. today announced a research collaboration agreement with Othair Prothena Limited, a subsidiary of Prothena Corporation plc (Prothena), which will enable Prothena to use Cerveau’s [F-18]MK-6240, an investigational imaging agent, in Positron Emission Tomography (PET) scans to assess the status and progression of neurofibrillary tangles (NFTs) in the brain.

Virpax® Pharmaceuticals, Inc. announced that the Company has engaged Destum Partners, Inc. to serve as the exclusive advisor for the Company’s partnering and licensing efforts in strategic global markets.